Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02379741 | ADC-1013 First-in-Human Study | completed | Phase 1 | 24 | Alligator Bioscience ABINDUSTRY | 3 | Mar 27, 2017 | clinicaltrials |
| NCT00878904 | Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors | completed | Phase 1 | 40 | University of California, San FranciscoOTHER | 1 | Mar 24, 2017 | clinicaltrials |
| NCT01537744 |
| A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Virally Mediated Cancers and Liposarcoma |
| completed |
| Phase 1 |
| 18 |
| Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER |
| 1 |
| Mar 24, 2017 |
| clinicaltrials |
| NCT00662636 | Dasatinib and Lapatinib Ditolsylate in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery | completed | Phase 1 | 27 | Mayo ClinicOTHER | 1 | Mar 23, 2017 | clinicaltrials |
| NCT01444456 | Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia | completed | — | 1,262 | AmgenINDUSTRY | 9 | Mar 20, 2017 | clinicaltrials |
| NCT01626547 | Biosimilar Retacrit™ (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology | completed | — | 291 | Hospira, now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Mar 20, 2017 | clinicaltrials |
| NCT00091247 | Tetracycline in Preventing Skin Rash in Patients Who Are Receiving Drugs Such as Gefitinib and Cetuximab for Cancer | completed | N/A | 130 | Alliance for Clinical Trials in OncologyOTHER | 1 | Mar 16, 2017 | clinicaltrials |
| NCT00296036 | Pyridoxine and Topical Urea/Lactic Acid-Based Cream in Preventing Hand-Foot Syndrome in Patients Receiving Capecitabine for Breast Cancer or Other Cancer | completed | Phase 3 | 137 | Alliance for Clinical Trials in OncologyOTHER | 1 | Mar 16, 2017 | clinicaltrials |
| NCT01516645 | Phase 1 Study of KHK2898 in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 14 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Mar 16, 2017 | clinicaltrials |
| NCT00311597 | Extracranial Stereotactic Radiosurgery in Treating Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 48 | Wake Forest University Health SciencesOTHER | 1 | Mar 14, 2017 | clinicaltrials |
| NCT00551512 | Phase I Study of CBP501 and Cisplatin in Patients With Advanced Refractory Solid Tumors | completed | Phase 1 | 48 | CanBas Co. Ltd.INDUSTRY | 1 | Mar 14, 2017 | clinicaltrials |
| NCT00458887 | Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin | completed | — | 301 | Children's Oncology GroupNETWORK | 3 | Mar 13, 2017 | clinicaltrials |
| NCT02450149 | Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib, in Subjects With BRAF Mutation Refractory Solid Tumors | completed | N/A | 1 | Samsung Medical CenterOTHER | 1 | Mar 13, 2017 | clinicaltrials |
| NCT01049841 | Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors | completed | Phase 1 | 23 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 10, 2017 | clinicaltrials |
| NCT01449370 | Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer | completed | Phase 1 | 125 | Millennium Pharmaceuticals, Inc.INDUSTRY | 3 | Mar 9, 2017 | clinicaltrials |
| NCT01390818 | Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 146 | EMD SeronoINDUSTRY | 3 | Mar 7, 2017 | clinicaltrials |
| NCT02216669 | Trial to Determine Optimal Phase II Dose of the Oral Dual CAIX Inhibitor/ Radiosensitizer | withdrawn | Phase 1 | 0 | Maastricht Radiation OncologyOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT03062982 | Food-Effect and Metabolism Study in Healthy Subjects | completed | Phase 1 | 16 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 24, 2017 | clinicaltrials |
| NCT02449538 | Study to Evaluate the Safety and Efficacy of Everolimus, in Subjects With PIK3CA Amplification, PTEN Loss and PIK3CA Mutation Refractory Solid Tumors | completed | Phase 2 | 10 | Samsung Medical CenterOTHER | 1 | Feb 17, 2017 | clinicaltrials |
| NCT01299701 | A Single Center Study to Characterize the Absorption, Distribution, Metabolism and Excretion (ADME) of ASA404 After a Single Infusion in Patients With Solid Tumors | terminated | Phase 1 | 7 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 14, 2017 | clinicaltrials |
| NCT01504490 | Phase I Study of CS-7017 and Bexarotene | terminated | Phase 1 | 9 | Georgetown UniversityOTHER | 1 | Feb 14, 2017 | clinicaltrials |
| NCT02262455 | Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors | completed | Phase 1 | 32 | Santa Maria BiotherapeuticsINDUSTRY | 1 | Feb 13, 2017 | clinicaltrials |
| NCT02890511 | A Study DHP107, a Novel Oral Paclitaxel Formulation, in Patients With Advanced Solid Tumours or Gastric Cancer | completed | Phase 1 / Phase 2 | 28 | Daehwa Pharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 13, 2017 | clinicaltrials |
| NCT00416624 | Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy | completed | Phase 2 | 239 | Mayo ClinicOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT00585221 | Study of Imatinib and Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) Patients | terminated | Phase 2 | 8 | University of UtahOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT00719563 | American Ginseng in Treating Patients With Fatigue Caused by Cancer | completed | Phase 3 | 364 | Alliance for Clinical Trials in OncologyOTHER | 1 | Feb 9, 2017 | clinicaltrials |
| NCT01489826 | A Phase 1 Study of Dexanabinol in Patients With Advanced Solid Tumours | completed | Phase 1 | 40 | e-Therapeutics PLCINDUSTRY | 1 | Feb 9, 2017 | clinicaltrials |
| NCT03045003 | Testing Two Different Intensities of an Intervention to Enhance REsilience and to Reduce SupportIve Care Needs in Cancer Patients(RESIL) | completed | N/A | 86 | Manuela EicherOTHER | 0 | Feb 9, 2017 | clinicaltrials |
| NCT03047811 | The Study of Targeted NY-ESO-1 T Cell Receptor (TCR) Genetic Modified Autologous T Cells Treatment of Advanced Solid Tumors | unknown | N/A | 15 | Fudan UniversityOTHER | 1 | Feb 9, 2017 | clinicaltrials |
| NCT00861419 | To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib. | completed | Phase 1 | 88 | AmgenINDUSTRY | 0 | Feb 8, 2017 | clinicaltrials |
| NCT02048709 | Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors | completed | Phase 1 | 22 | Genentech, Inc.INDUSTRY | 1 | Feb 6, 2017 | clinicaltrials |
| NCT00019604 | Radiofrequency Ablation in Treating Patients With Unresectable Primary or Metastatic Liver Cancer | terminated | Phase 2 | 44 | National Institutes of Health Clinical Center (CC)NIH | 1 | Feb 3, 2017 | clinicaltrials |
| NCT02536469 | HuMax-IL8 (Interleukin8) in Patients With Advanced Malignant Solid Tumors | completed | Phase 1 | 15 | Bristol-Myers SquibbINDUSTRY | 1 | Feb 3, 2017 | clinicaltrials |
| NCT00004927 | BMS-247550 in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy | completed | Phase 1 | — | R-PharmINDUSTRY | 1 | Jan 30, 2017 | clinicaltrials |
| NCT01018966 | Study of Ixabepilone (BMS-247550) in Patients With Solid Tumors | completed | Phase 1 | 25 | R-PharmINDUSTRY | 0 | Jan 30, 2017 | clinicaltrials |
| NCT01406119 | An Extension Study of ABT-806 in Subjects With Advanced Solid Tumors | completed | Phase 1 | 14 | AbbVie (prior sponsor, Abbott)INDUSTRY | 2 | Jan 27, 2017 | clinicaltrials |
| NCT01980667 | Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors | completed | Phase 1 | 41 | PharmaMarINDUSTRY | 2 | Jan 26, 2017 | clinicaltrials |
| NCT01721148 | A Phase I Multiple Ascending Dose Study of ASLAN002 in Subjects With Advanced or Metastatic Solid Tumours | completed | Phase 1 | 39 | ASLAN PharmaceuticalsOTHER | 0 | Jan 25, 2017 | clinicaltrials |
| NCT03030001 | PD-1 Antibody Expressing CAR T Cells for Mesothelin Positive Advanced Malignancies | unknown | Phase 1 / Phase 2 | 40 | Ningbo Cancer HospitalINDUSTRY | 1 | Jan 24, 2017 | clinicaltrials |
| NCT00003657 | High-dose ICE With Amifostine | completed | Phase 2 | 24 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 20, 2017 | clinicaltrials |
| NCT00607802 | Donor White Blood Cell Infusion in Treating Patients With Metastatic or Unresectable Cancer | withdrawn | N/A | 0 | Wake Forest University Health SciencesOTHER | 0 | Jan 19, 2017 | clinicaltrials |
| NCT00972634 | Computerized Questionnaires in Assessing Symptoms, Pain, Depression, and Physical Function in Patients With Metastatic and/or Advanced Locoregional Cancer | completed | — | 1,051 | Norwegian University of Science and TechnologyOTHER | 1 | Jan 18, 2017 | clinicaltrials |
| NCT01929603 | Study to Assess the Effect of Rifampicin (CYP Inducer) on Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours | completed | Phase 1 | 32 | AstraZenecaINDUSTRY | 2 | Jan 16, 2017 | clinicaltrials |
| NCT00550654 | Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain | terminated | Phase 2 | 1 | National Institutes of Health Clinical Center (CC)NIH | 1 | Jan 13, 2017 | clinicaltrials |
| NCT00608855 | Percutaneous Cryoablation in Treating Patients With Painful Bone Metastases | completed | N/A | 60 | Mayo ClinicOTHER | 1 | Jan 12, 2017 | clinicaltrials |
| NCT00949949 | Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy | completed | Phase 1 | 38 | Mayo ClinicOTHER | 1 | Jan 12, 2017 | clinicaltrials |
| NCT00555724 | Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors | completed | Phase 1 | 40 | BiogenINDUSTRY | 1 | Jan 9, 2017 | clinicaltrials |
| NCT00725933 | Administration of BIIB028 to Subjects With Solid Tumors | completed | Phase 1 | 43 | BiogenINDUSTRY | 1 | Jan 9, 2017 | clinicaltrials |
| NCT00970411 | Study of KRN951 in Patients With Solid Tumors | completed | Phase 1 | 12 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Jan 5, 2017 | clinicaltrials |
Data updated 24 days agoSource updated Mar 27, 2017source: clinicaltrials